Cellectis SA Receives a Buy from Oppenheimer

By Carrie Williams

Oppenheimer analyst Hartaj Singh maintained a Buy rating on Cellectis SA (NASDAQ: CLLS) yesterday and set a price target of $44. The company’s shares closed yesterday at $30.21.

Singh said:

“Cellectis (CLLS) announced on 6/4 that the FDA approved its IND filing for 30-day review period (filed early May). The IND is for CLLS’ third allogeneic (off-the-shelf) UCART candidate, UCART22, in acute B-cell lymphoblastic leukemia (B-ALL). CLLS plans to initiate the Phase 1 study in 3Q18. After incorporating UCART22 into our model, we are raising our price target to $44 (from $40 previously) and remain bullish.”

According to TipRanks.com, Singh is a 4-star analyst with an average return of 16.9% and a 50.8% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Cellectis SA has an analyst consensus of Moderate Buy, with a price target consensus of $58.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $38.85 and a one-year low of $21.25. Currently, Cellectis SA has an average volume of 316.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.